Elizabeth Mutisya, Solvay Pharmaceuticals
I started my career as a medical liaison. It was a wonderful opportunity to shape how companies and physicians further scientific understanding of difficult medical problems, focus on key research questions, and address unmet patient needs.
Elizabeth Mutisya
Vice President, US Medical Affairs, Chief Medical Officer, Solvay Pharmaceuticals
I started my career as a medical liaison. It was a wonderful opportunity to shape how companies and physicians further scientific understanding of difficult medical problems, focus on key research questions, and address unmet patient needs. I am proud that I have been able to focus the companies I've been part of on the hidden value in existing or prospective assets—a creative approach to planning for the future. At each juncture, I have been open to the full range of possibilities, and have taken the time to think about which of several paths made the most sense given my personal mission to have a tangible, positive impact on patients, my community, and the health of society at large.
Ultimately, we need to do a better job of delineating the value that our industry provides in addressing medical problems. Health economics and outcomes research is one way we can accomplish this. It allows us to better quantify the benefits of our solutions to patient outcomes, health-related quality of life, and individuals involved in patient care. It also enables us to think more holistically about the impact of a particular intervention or preventive measure on overall healthcare costs. At Solvay, I have focused on this and other ways we can prepare for the healthcare environment of tomorrow.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Merck’s Oral TLR7/8 Inhibitor Reduces Disease Activity in Cutaneous, Systemic Lupus
May 21st 2025Results from the Phase II WILLOW trial show that enpatoran achieved a statistically significant dose-response and clinically meaningful reduction in disease activity in cutaneous and systemic lupus erythematosus with active rash.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
